Abstract：
The FDA has approved many nucleic acid (NA)-based products. The presence of charges and biological barriers however affect stability and restrict widespread use. The electrostatic complexation of peptide with polyethylene glycol-nucleic acids (PEG-NAs) via nonreducible and reducible agents lead to three parts at one platform.. The reducible linkage made detachment of siRNA from PEG easy compared with a nonreducible linkage. A peptide spider produces a small hydrodynamic particle size, which can improve drug release and pharmacokinetics. Several examples of peptide spiders that enhance stability, protection and transfection efficiency are discussed. Moreover, this review also covers the challenges, future perspectives and unmet needs of peptide-PEG-NAs conjugates for NAs delivery.
摘要：
FDA已经批准了许多基于核酸(NA)的产品。然而,电荷和生物屏障的存在影响稳定性并限制广泛使用。在一个系统中出现了三个部分，即，通过不可还原和还原剂将肽与PEG-NA静电复合。与非可还原连接相比,可还原连接使siRNA容易从PEG脱离。肽蜘蛛产生小的流体动力学颗粒大小，可以改善药物释放和药代动力学。增强稳定性的肽蜘蛛的几个例子，保护和转染效率进行了讨论。此外，这次审查也涵盖了挑战，肽蜘蛛的未来前景和未满足的需求。
